Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 1163-1167

  Kogashiwa, Yasunao ^a   Yamauchi, Kohichi ^a   Nagafuji, Hiroshi ^a   Matsuda, Takehiro ^a   Tsubosaka, Toshihito ^a   Tsutsumi, Tomoko ^a   Karaho, Takehiro ^a   Kohno, Naoyuki ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Concurrent chemoradiotherapy; Docetaxel; Induction chemotherapy; Nedaplatin; Phase I study

Indexed keywords

DOCETAXEL; NEDAPLATIN;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HYPOPHARYNX CANCER; LARYNGECTOMY; LARYNX CANCER; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; SALVAGE THERAPY; SEIZURE; STOMATITIS; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70449412178     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000550     Document Type: Article

References (14)

1. Krengli M, Policarpo M, Manfredda I, et al: Voice quality after treatment for t1a glottic carcinoma - radiotherapy versus laser cordectomy. Acta Oncol 43: 284-289, 2004.
2. Luscher MS, Pedersen U and Johansen LV: Treatment outcome after laser excision of early glottic squamous cell carcinoma - a literature survey. Acta Oncol 40: 796-800, 2001.
3. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091-2098, 2003.
4. Ferlito A, Silver CE, Howard DJ, Laccourreye O, Rinaldo A and Owen R: The role of partial laryngeal resection in current management of laryngeal cancer: a collective review. Acta Otolaryngol 120: 456-465, 2000.
5. Laccourreye H, Laccourreye O, Weinstein G, Menard M and Brasnu D: Supracricoid laryngectomy with cricohyoidoepiglottopexy: a partial laryngeal procedure for glottic carcinoma. Ann Otol Rhinol Laryngol 99: 421-426, 1990.
6. Motamed M, Laccourreye O and Bradley PJ: Salvage conservation laryngeal surgery after irradiation failure for early laryngeal cancer. Laryngoscope 116: 451-455, 2006.
7. Alcock CJ, Fowler JF, Haybittle JL, Hopewell JW, Rezvani M and Wiernik G: Salvage surgery following irradiation with different fractionation regimes in the treatment of carcinoma of the laryngo pharynx: experience gained from a British institute of radiology study. J Laryngol Otol 106: 147-153, 1992.
8. Fowler BZ, Muller S, Chen AY and Johnstone PA: Factors influencing long-term survival following salvage total laryngectomy after initial radiotherapy or conservative surgery. Head Neck 28: 99-106, 2006.
9. Weiss RB and Christian MC: New cisplatin analogues in development. A review. Drugs 46: 360-377, 1993.
10. Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M and Gemba M: Nephrotoxicity of a new platinum compound, 254-s, evaluated with rat kidney cortical slices. Toxicol Lett 52: 15-24, 1990.
11. Suzumura Y, Kato T, Ueda R and Ota K: Effect of treatment schedule on antitumor activity of glycolate-0,0′-diammineplatinum(ii), a new platinum derivative: comparison with cisdiamminedichloroplatinum(ii). Anticancer Res 9: 1083-1088, 1989.
12. Kanzawa F, Matsushima Y, Nakano H, et al: Antitumor activity of a new platinum compound (glycolate-o,o′) diammineplatinum (ii) (254-s), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system. Anticancer Res 8: 323-327, 1988.
13. Akaza H, Togashi M, Nishio Y, et al: Phase II study of cisdiammine(glycolato)platinum, 254-s, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-s urological cancer study group. Cancer Chemother Pharmacol 31: 187-192, 1992.
14. Hartmann JT and Lipp HP: Toxicity of platinum compounds. Expert Opin Pharmacother 4: 889-901, 2003.